@article{5cad72b84035490793cca8c3d4e780e8,
title = "Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions",
abstract = "Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.",
keywords = "MS PATHS, Multiple sclerosis, SARS-COV-2 vaccination, disease-modifying therapy, humoral immune response, optimal management",
author = "Cohen, {Jeffrey A.} and Bermel, {Robert A.} and Grossman, {Cynthia I.} and Hersh, {Carrie M.} and Megan Hyland and Mowry, {Ellen M.} and Robert Naismith and Naylor, {Maria L.} and Jacqueline Nicholas and Rajani Rajbhandar and Singh, {Carol M.} and Mar Tintor{\`e} and Ana Zabalza and Tjalf Ziemssen and Williams, {James R.} and Xavier Montalban",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.A.C. reports receiving personal compensation for consulting from Biogen, Bristol Myers Squibb, Convelo, Genentech, Janssen, NervGen, Novartis, and PSI; speaking for H3 Communications; and serving as an Editor of Multiple Sclerosis Journal. R.A.B. reports being on the scientific advisory board and/or doing consulting for Biogen, EMD Serono, Genentech/Roche, Novartis, Sanofi/Genzyme, and Viela Bio and receiving research support from Biogen, Novartis, and Roche. C.M.H. reports receiving speaking and consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, and Novartis and grants/research support from Biogen, Genentech, NIH–NINDS 1U01NS111678-01A1 sub-award, Novartis, and Patient-Centered Outcomes Research Institute (PCORI). M.H. reports receiving research support from Biogen and PCORI. E.M.M. reports receiving research support from Biogen, Genentech, and Teva and royalties from UpTo Date (editorial duties). R.N. reports being on the scientific advisory board and/or doing consulting for Avidea, Biogen, Bristol Myers Squibb, Genentech, Genzyme, GW Therapeutics, Horizon Therapeutics, Janssen, Lundbeck, Nervgen, TG Therapeutics, Third Rock Ventures, and Viela Bio. J.N. reports receiving research grants from ADAMAS, Biogen, Genzyme, Novartis, and PCORI and consulting and/or speaking fees from Alexion, Bristol Myers Squib, EMD Serono, Genetech, Greenwich Biosciences, Novartis, and Viela Bio. M.T. has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen, Genzyme, Janssen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio, and Teva Pharmaceuticals and is the co-editor of Multiple Sclerosis Journal-ETC. A.Z. has received travel expenses for scientific meetings from Biogen and Novartis, speaking honoraria from Eisai, and a study grant from Novartis. T.Z. reports being on the scientific advisory board and/or doing consulting for Biogen, Celgene, Merck, Novartis, and Roche; receiving compensation for serving on speakers bureaus for Biogen, Celgene, Merck, Novartis, Roche, and Sanofi; and receiving research support from Biogen, Celgene, Merck, Novartis, and Sanofi. X.M. reports receiving speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, MedDay, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS. C.I.G., C.M.S., and J.R.W. are employees of and shareholders/stockholders of Biogen. R.R. and M.L.N. are shareholder/stockholders and former employees of Biogen. Publisher Copyright: {\textcopyright} The Author(s), 2022.",
year = "2022",
month = jun,
doi = "10.1177/13524585211061343",
language = "English",
volume = "28",
pages = "1131--1137",
journal = "Multiple Sclerosis",
issn = "1352-4585",
number = "7",
}